The Food and Drug Administration (FDA) is working on improving access to higher doses of transmucosal buprenorphine, a medication commonly used to treat opioid addiction. The rise of fentanyl and other potent synthetic opioids has made standard dosages less effective for some individuals, leading to the push for stronger, more accessible treatment options. If approved, these changes could allow doctors to prescribe more flexible doses, potentially reducing withdrawal symptoms and increasing the success rate of Medication-Assisted Treatment.